Terry Kenakin

17.1k citations

205 papers · 12.9k indexed · 3 hit papers · h-index 57

Impact in

Cellular and Molecular Neuroscience top 0.1%
- Neuropeptides and Animal Physiology
- Neuroscience and Neuropharmacology Research
- Neurotransmitter Receptor Influence on Behavior
Molecular Biology top 0.2%
- Receptor Mechanisms and Signaling
- Protein Kinase Regulation and GTPase Signaling
- Pharmacological Receptor Mechanisms and Effects

Papers in

Cellular and Molecular Neuroscience 92
- Neuropeptides and Animal Physiology 70
- Neuroscience and Neuropharmacology Research 16
- Neurotransmitter Receptor Influence on Behavior 10
Computational Theory and Mathematics 48
- Computational Drug Discovery Methods 48

Co-authors: Arthur Christopoulos Laurence J. Miller Christian Watson Paul H. Morgan Stephen Jenkinson Michael Spedding Richard R. Neubig Michael W. Lutz
Journals: Trends in Pharmacological Sciences (31 papers)Molecular Pharmacology (19 papers)Journal of Pharmacology and Experimental Therapeutics (18 papers)British Journal of Pharmacology (11 papers)Nature Reviews Drug Discovery (7 papers)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Terry Kenakin

199 papers receiving 12.5k citations

Hit Papers

align trajectories log scale

Signalling bias in new drug discovery: detection, quantification and therapeutic impact 2012 · 587 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Nature Reviews Drug Discovery
1995 Trends in Pharmacological Sciences
1995 Nature

Peers

Countries citing papers authored by Terry Kenakin

Since Specialization

Citations

This map shows the geographic impact of Terry Kenakin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry Kenakin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry Kenakin more than expected).

Fields of papers citing papers by Terry Kenakin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry Kenakin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry Kenakin. The network helps show where Terry Kenakin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Terry Kenakin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Terry Kenakin Line = papers co-authored together Terry Kenakin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Molecular mechanisms of inverse agonism via κ-opioid receptor–G protein complexes Nature Chemical Biology ·Neils Hansen, Saif Ur Rehman Khan, Shigeyuki Hirayama, Gye Won Han, A. V. Bgatov, M. Miklas, Voič Kocman, Sheng Yuan-sheng, Sergey S. Lantukhov, Ann-Charlotte Söder, E. Lagrange, Terry Kenakin, Ryan A. Shenvi, Susruta Majumdar, Cornelius Gati	2025	3
2	Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition Nature Reviews Drug Discovery ·Terry Kenakin	2024	9
3	Allostery: The Good, the Bad, and the Ugly Journal of Pharmacology and Experimental Therapeutics ·Terry Kenakin	2023	7
4	Neurotensin Receptor Allosterism Revealed in Complex with a Biased Allosteric Modulator Biochemistry ·B. Krumm, Jeffrey F. DiBerto, Reid H. J. Olsen, Hye Jin Kang, Samuel T. Slocum, Shicheng Zhang, Ryan T. Strachan, Xi‐Ping Huang, Lauren M. Slosky, Anthony B. Pinkerton, Lawrence S Barak, Marc G. Caron, Terry Kenakin, Jonathan F. Fay, Bryan L. Roth	2023	36
5	Community guidelines for GPCR ligand bias: IUPHAR review 32 British Journal of Pharmacology ·Peter Kolb, Terry Kenakin, S P H Alexander, Marcel Bermúdez, Laura Bohn, Arthur Stérin, Michel Bouvier, Stephen J. Hill, Evi Kostenis, Kirill A. Martemyanov, Thitima Rungrattanaubon, H. Ongun Onaran, Sudarshan Rajagopal, Bryan L. Roth, Jana Selent, Arun K. Shukla, M. Sommer, David E. Gloriam	2022	121
6	Interdependent allosteric free fatty acid receptor 2 modulators synergistically induce functional selective activation and desensitization in neutrophils Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Lin Hemin, André Holdfeldt, Jonas Mårtensson, Martina Sundqvist, Terry Kenakin, Lena Björkman, Huamei Forsman, Cláes Dahlgren	2020	22
7	Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7 Cell chemical biology ·Kelsey N. Lamb, RD Linke, Timothy S. Roach, Krishnan K. K. Dilip, Huitao Fan, Jacob I. Stuckey, Jacqueline L. Norris, Stephanie H. Cholensky, Dongxu Li, Jingkui Wang, Cari A. Sagum, Benjamin Z. Stanton, Mark T. Bedford, Kenneth H. Pearce, Terry Kenakin, Dmitri Kireev, Gang Greg Wang, Lindsey I. James, Oliver Bell, Stephen V. Frye	2019	42
8	A Molecular Mechanism for Sequential Activation of a G Protein-Coupled Receptor Cell chemical biology ·Manuel Grundmann, Irina G. Tikhonova, Brian D. Hudson, Nicola J. Smith, Klaus Mohr, Trond Ulven, Graeme Milligan, Terry Kenakin, Evi Kostenis	2016	32
9	Quantifying Biased β-Arrestin Signaling Handbook of experimental pharmacology ·Terry Kenakin	2013	14
10	Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nature Reviews Drug Discovery ·Terry Kenakin, Arthur Christopoulos Hit paper breakdown →	2012	587
11	G protein coupled receptors as allosteric proteins and the role of allosteric modulators Journal of Receptors and Signal Transduction ·Terry Kenakin	2010	34
12	Interrogating 7TM receptors: Does texture in the question yield greater texture in the answer? Journal of Receptors and Signal Transduction ·Terry Kenakin	2009	6
13	Peptide, Peptidomimetic and Small‐molecule Drug Discovery Targeting HIV‐1 Host‐cell Attachment and Entry through gp120, gp41, CCR5 and CXCR4^† Chemical Biology & Drug Design ·Wieslaw M. Kazmierski, Terry Kenakin, Kristjan S. Gudmundsson	2005	37
14	The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor Molecular Pharmacology ·Christian Watson, Stephen Jenkinson, Wieslaw M. Kazmierski, Terry Kenakin	2005	218
15	The Use of Stimulus-Biased Assay Systems to Detect Agonist-Specific Receptor Active States: Implications for the Trafficking of Receptor Stimulus by Agonists Molecular Pharmacology ·Chris Watson, Grace Chen, Hung Tan, James M. Way, Wen-Ji Chen, Terry Kenakin	2000	14
16	The relative importance of the time‐course of receptor occupancy and response decay on apparent antagonist potency in dynamic assays Journal of Autonomic Pharmacology ·M. Corsi, Terry Kenakin	2000	2
17	Constitutive receptor systems for drug discovery Journal of Pharmacological and Toxicological Methods ·Grace Chen, Channa Jayawickreme, James M. Way, Susan Armour, Anne Wilson McWaters, Chris Watson, Diane M. Ignar, Wen-Ji Chen, Terry Kenakin	1999	26
18	On the importance of the “antagonist assumption” to how receptors express themselves Biochemical Pharmacology ·Terry Kenakin, Paul H. Morgan, Michael W. Lutz	1995	39
19	Agonist-receptor efficacy II: agonist trafficking of receptor signals Trends in Pharmacological Sciences ·Terry Kenakin Hit paper breakdown →	1995	544
20	Are receptors promiscuous? Intrinsic efficacy as a transduction phenomenon Life Sciences ·Terry Kenakin	1988	36

About Terry Kenakin

Terry Kenakin is a scholar working on Cellular and Molecular Neuroscience, Computational Theory and Mathematics, Molecular Biology, Animal Science and Zoology and Virology, having authored 205 papers that have together received 12.9k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (164 papers), Neuropeptides and Animal Physiology (70 papers), Computational Drug Discovery Methods (48 papers), Monoclonal and Polyclonal Antibodies Research (31 papers), Pharmacological Effects and Assays (24 papers), Neuroscience and Neuropharmacology Research (16 papers), Chemical Synthesis and Analysis (14 papers) and Neurotransmitter Receptor Influence on Behavior (10 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (6.6k citations), Molecular Biology (10.0k citations), Computational Theory and Mathematics (1.4k citations), Physiology (394 citations) and Endocrine and Autonomic Systems (504 citations). Terry Kenakin has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include Arthur Christopoulos, Laurence J. Miller, Christian Watson, Paul H. Morgan, Stephen Jenkinson, Michael Spedding, Richard R. Neubig, Michael W. Lutz, Wieslaw M. Kazmierski and Vanessa Muniz‐Medina. Their work appears in journals such as Trends in Pharmacological Sciences, Molecular Pharmacology, Journal of Pharmacology and Experimental Therapeutics, British Journal of Pharmacology and Nature Reviews Drug Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact